JP2004527244A - 受容体型キナーゼ阻害剤の活性のインビボ測定方法 - Google Patents

受容体型キナーゼ阻害剤の活性のインビボ測定方法 Download PDF

Info

Publication number
JP2004527244A
JP2004527244A JP2002577907A JP2002577907A JP2004527244A JP 2004527244 A JP2004527244 A JP 2004527244A JP 2002577907 A JP2002577907 A JP 2002577907A JP 2002577907 A JP2002577907 A JP 2002577907A JP 2004527244 A JP2004527244 A JP 2004527244A
Authority
JP
Japan
Prior art keywords
receptor
kdr
kinase
kinase receptor
vivo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2002577907A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004527244A5 (cg-RX-API-DMAC10.html
Inventor
トーマス，ケネス・エイ，ジユニア
マオ，シヤンチー
ケンドール，リチヤード・エル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of JP2004527244A publication Critical patent/JP2004527244A/ja
Publication of JP2004527244A5 publication Critical patent/JP2004527244A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2002577907A 2001-04-02 2002-03-29 受容体型キナーゼ阻害剤の活性のインビボ測定方法 Withdrawn JP2004527244A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28077101P 2001-04-02 2001-04-02
PCT/US2002/009758 WO2002079498A1 (en) 2001-04-02 2002-03-29 In vivo methods of determining activity of receptor-type kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2004527244A true JP2004527244A (ja) 2004-09-09
JP2004527244A5 JP2004527244A5 (cg-RX-API-DMAC10.html) 2005-12-22

Family

ID=23074563

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002577907A Withdrawn JP2004527244A (ja) 2001-04-02 2002-03-29 受容体型キナーゼ阻害剤の活性のインビボ測定方法

Country Status (4)

Country Link
EP (1) EP1385983A4 (cg-RX-API-DMAC10.html)
JP (1) JP2004527244A (cg-RX-API-DMAC10.html)
CA (1) CA2443144A1 (cg-RX-API-DMAC10.html)
WO (1) WO2002079498A1 (cg-RX-API-DMAC10.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
EA017648B1 (ru) 2007-09-14 2013-02-28 Орто-Макнейл-Янссен Фармасьютикалз, Инк. 1',3'-двузамещенные-4-фенил-3,4,5,6-тетрагидро-2н,1'н-[1,4']бипириди-нил-2'-оны
JP5547194B2 (ja) 2008-09-02 2014-07-09 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体の調節因子としての３−アザビシクロ［３．１．０］ヘキシル誘導体
JP5690277B2 (ja) 2008-11-28 2015-03-25 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体
AU2010232729A1 (en) 2009-03-31 2011-10-20 Arqule, Inc. Substituted indolo-pyridinone compounds
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN102439015B (zh) 2009-05-12 2015-05-13 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物和其作为mGluR2受体的正向变构调节剂的用途
HRP20131122T1 (hr) 2009-05-12 2013-12-20 Janssen Pharmaceuticals, Inc. Derivati 1,2,4-triazolo[4,3-a] piridina i njihova uporaba u lijeäśenju ili prevenciji neuroloških i psihijatrijskih poremeä†aja
JP5852664B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
ES2536433T3 (es) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
EP2661435B1 (en) 2010-11-08 2015-08-19 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
ME03518B (me) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
PL3096790T3 (pl) 2014-01-21 2020-01-31 Janssen Pharmaceutica, N.V. Kombinacje zawierające pozytywne modulatory allosteryczne lub agonistów ortosterycznych metabotropowego receptora glutaminergicznego podtypu 2 i ich zastosowanie

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US5783568A (en) * 1994-06-10 1998-07-21 Sugen, Inc. Methods for treating cancer and other cell proliferative diseases
US6271233B1 (en) * 1999-08-10 2001-08-07 Ciba Vision Corporation Method for treating ocular neovascular diseases

Also Published As

Publication number Publication date
CA2443144A1 (en) 2002-10-10
EP1385983A4 (en) 2005-11-16
WO2002079498A1 (en) 2002-10-10
EP1385983A1 (en) 2004-02-04

Similar Documents

Publication Publication Date Title
Tugues et al. Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats
Beyer et al. Tyrosine kinase signaling in fibrotic disorders: translation of basic research to human disease
WO2002079498A1 (en) In vivo methods of determining activity of receptor-type kinase inhibitors
JP7037836B2 (ja) タンパク質キナーゼ阻害剤に対する感受性予測用バイオマーカー及びその用途
CA2802984C (en) Use of eph-b4 and ephrin-a1 for predicting negative physiological response to the treatment with erythropoietin
AU2009331955B2 (en) Biomarkers for inhibitors with anti-angiogenic activity
Fletcher Role of KIT and platelet-derived growth factor receptors as oncoproteins
Guha Ras activation in astrocytomas and neurofibromas
TW202043482A (zh) 用於治療海帕西啶(hepcidin)介導之病症之方法
Windhofer et al. Marked dependence on growth state of backup pathways of NHEJ
KR20230093429A (ko) 알킨 치환된 퀴나졸린 유도체로 암을 치료하는 방법
Yu et al. Efficacy of the novel selective platelet-derived growth factor receptor antagonist CT52923 on cellular proliferation, migration, and suppression of neointima following vascular injury
US20060159676A1 (en) Methods for modulating angiogenesis, lymphangiogenesis, and apoptosis with apelin compositions
US20250228826A1 (en) Combination of a gremlin-1 antagonist with an inhibitor of ras-raf-mek-erk signalling
JP2007528861A (ja) 心肥大及びそれに起因する心疾患を予防または治療するための医薬組成物
CN103764847A (zh) 对于kras基因突变型的结肠直肠癌患者的抗肿瘤剂和治疗效果预测方法
Belda-Iniesta et al. Epidermal growth factor receptor and glioblastoma multiforme: molecular basis for a new approach
US20040101478A1 (en) In vivo methods of determining activity of receptor-type kinase inhibitors
Jiang et al. The Abl/Abi signaling links WAVE regulatory complex to Cbl E3 ubiquitin ligase and is essential for breast cancer cell metastasis
Bold et al. CGP 79787D (PTK787/ZK222584), CGP 84738, NVP-AAC789, NVP-AAD777 and related 1-anilino-(4-pyridyl methyl) phthalazines as inhibitors of VEGF-induced angiogenesis
CN111139299B (zh) Josd2蛋白在制备治疗恶性肿瘤药物中的应用
KR20100037639A (ko) Ｅｇｆｒ 억제제를 이용한 치료에 대한 예측 마커
JPWO2007026969A1 (ja) 創薬標的タンパク質及び標的遺伝子、並びにスクリーニング方法
US20160083799A1 (en) Mutations in pdgfrb and notch3 as causes of autosomal dominant infantile myofibromatosis
Newton Overview of the molecular genetics and molecular chemotherapy of GBM

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050307

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050307

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20070226